Deliver
Evaluate whether BactPac reaches the intended cells and makes cargo available inside them.
Science
Evidence across the delivery sequence.
SiVEC engineers BactPac to deliver functional therapeutic cargo inside target cells and translate that delivery into meaningful preclinical activity.
Scientific approach
From intracellular delivery to program activity.
BactPac programs are evaluated in a deliberate sequence. SiVEC first confirms delivery, then measures payload function, and finally advances complete therapeutic configurations into disease-relevant models.
All findings described on this page are preclinical and remain specific to the tested payload, route, and model.
Confirm activity
Measure whether the delivered payload remains biologically active in the target cell.
Advance the program
Test the complete therapeutic configuration in disease-relevant preclinical models.
Platform evidence
One platform. Multiple therapeutic directions.
BactPac delivers biologically active protein and RNA payloads inside target cells in preclinical studies. The platform has generated evidence across intracellular biologics, RNA therapeutics, oncology, respiratory antivirals, and gene editing.
Intracellular delivery
Biologically active protein and RNA payloads
BactPac produces and delivers functional protein and RNA cargo directly inside target cells.
Oncology activity
Broad activity across RAS-driven cancer models
SVC-KRAb inhibits RAS-driven cancer-cell growth across multiple models and suppresses tumor growth in vivo.
Combination potential
Chemotherapy sensitization
A Survivin-directed program increases tumor-cell sensitivity to chemotherapy, supporting combination strategies designed to improve treatment response.
Respiratory antiviral activity
Suppression of influenza replication
SiVEC-IAV suppresses influenza replication in cell and animal models following respiratory administration.
Gene-editing capability
Targeted gene-editing activity
BactPac produces functional gene-editing machinery capable of targeted DNA cleavage.
Lead-program evidence
SVC-KRAb advances BactPac into oncology.
SVC-KRAb is a first-in-class pan-RAS biologic designed to inhibit signaling driven by KRAS, NRAS, and HRAS. Its broad RAS targeting strategy is intended to address diverse RAS-driven tumors and mechanisms of resistance that can limit mutation-selective therapies.
Preclinical in vivo result
Up to 80%
Tumor-growth reduction
Observed in a mouse xenograft model compared with untreated controls. This result is preclinical and supports continued program development.
Broad RAS activity
Preclinical activity has been observed across multiple RAS-driven cancer models.
Multiple administration routes
The lead study evaluated both systemic and local administration.
Rabbit safety
Rabbit safety studies supported continued preclinical development in a model selected for its sensitivity to BactPac and relevance to human tolerability.